Get started
Author

Christopher L. Brooks

Observed names: C Brooks, C L Brooks, C. Brooks, C.L. Brooks, Chris Brooks, Chris L. Brooks, Christopher Brooks, Christopher L Brooks
Observed institutions: AstraZeneca (United Kingdom), Boston University, City Of Hope National Medical Center, The University of Texas MD Anderson Cancer Center, Emory University, Moffitt Cancer Center, Menarini Group (Italy), Dana-Farber Cancer Institute, Stemline Therapeutics (United States), The Ohio State University, Columbia University
ORCID: 0000-0003-3487-6644
Observed ORCID: 0000-0003-3487-6644
OpenAlex ID: A5001967177
p53 Ubiquitination: Mdm2 and Beyond
2006 · Christopher L. Brooks, Wei Gu · Molecular Cell · 923
PDF
Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2
2003 · Muyang Li, Christopher L. Brooks, et al. · Science · 803
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation
2003 · Christopher L Brooks, Wei Gu · Current Opinion in Cell Biology · 743
A Dynamic Role of HAUSP in the p53-Mdm2 Pathway
2004 · Muyang Li, Christopher L Brooks, et al. · Molecular Cell · 674
PDF
Acetylation of p53 Inhibits Its Ubiquitination by Mdm2
2002 · Muyang Li, Jianyuan Luo, et al. · Journal of Biological Chemistry · 503
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
2019 · Naveen Pemmaraju, Andrew A. Lane, et al. · New England Journal of Medicine · 437
PDF
How does SIRT1 affect metabolism, senescence and cancer?
2008 · Christopher L. Brooks, Wei Gu · Nature reviews. Cancer · 428
The impact of acetylation and deacetylation on the p53 pathway
2011 · Christopher L. Brooks, Wei Gu · Protein & Cell · 280
PDF
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
2014 · Arthur E. Frankel, Jung H. Woo, et al. · Blood · 235
p53 regulation by ubiquitin
2011 · Christopher L. Brooks, Wei Gu · FEBS Letters · 186
Inactivation of HAUSP in vivo modulates p53 function
2009 · N Kon, Y Kobayashi, et al. · Oncogene · 176
The p53–Mdm2–HAUSP complex is involved in p53 stabilization by HAUSP
2007 · C L Brooks, M Li, et al. · Oncogene · 145
New insights into p53 activation
2010 · Christopher L Brooks, Wei Gu · Cell Research · 127
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance
2019 · Katsuhiro Togami, Timothy Pastika, et al. · Journal of Clinical Investigation · 88
PDF
Dynamics in the p53-Mdm2 Ubiquitination Pathway
2004 · Christopher L. Brooks, Wei Gu · Cell Cycle · 88
PDF
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
2022 · Naveen Pemmaraju, Kendra L. Sweet, et al. · Journal of Clinical Oncology · 78
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent
2014 · F. Angelot-Delettre, A. Roggy, et al. · Haematologica · 64
PDF
Dynamics of the p53 Acetylation Pathway
2004 · Wei Gu, Jianyuan Luo, et al. · Novartis Foundation symposium · 57
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia
2023 · Andrew A. Lane, Jacqueline S. Garcia, et al. · Blood Advances · 53
PDF
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia
2017 · Lina Han, Jeffrey L. Jorgensen, et al. · Clinical Cancer Research · 49
PDF
Mechanistic Studies of MDM2-mediated Ubiquitination in p53 Regulation
2007 · Christopher L. Brooks, Muyang Li, et al. · Journal of Biological Chemistry · 48
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
2018 · Rajeswaran Mani, Swagata Goswami, et al. · Haematologica · 47
PDF
Monoubiquitination: The Signal for p53 Nuclear Export?
2004 · Christopher L. Brooks, Muyang Li, et al. · Cell Cycle · 43
PDF
SL ‐401 and SL ‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia
2014 · Olga Frolova, Juliana Benito, et al. · British Journal of Haematology · 42
A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells
2017 · A Ray, D S Das, et al. · Leukemia · 41
Works count: 118
Citation count: 6,976
H-index: 29
I10-index: 47
Year
Topic
Type